Observational analysis finds PRMT1 drives leukemogenesis through glycolysis and fatty acid oxidation in AMKL cells, suggesting metabolic targets for therapy.
Key Points
PRMT1 overexpression promotes leukemogenesis by enhancing glycolysis and reducing fatty acid oxidation.
Targeting PRMT1 with the inhibitor MS023 significantly improved outcomes in acute megakaryocytic leukemia.
Analysis showed PRMT1 increases glucose consumption while downregulating key fatty acid oxidation proteins like CPT1A.
Therapeutic strategies targeting metabolic pathways may help in treating PRMT1-driven leukemias effectively.